NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/11/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization231.59 mln
Float29.22 mln
Earnings Date05/07/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-0.18
Highly suspicious
1-Year Forecast
8.20
Transformational upside
Relative Strength
29
/ 100
Underperforming
Debt / Equity
0.04
Debt-free
ROE
-154
Deeply negative
Business Description
Camp4 Therapeutics is a clinical-stage company focused on developing RNA-based treatments for inherited genetic diseases. Its lead drug, CMP-001, is currently being tested in an early-stage clinical trial for urea cycle disorders, while a second treatment, CMP-002, targets SYNGAP1-related conditions. Founded in 2015 and based in Cambridge, Massachusetts, the company was previously called Marauder Therapeutics before rebranding in 2018.
